Novartis urges First Circuit not to revive sham litigation claim
A lower court correctly held that Novartis’s patent litigation against a generic drugmaker was not objectively baseless or motivated by anticompetitive intent, the pharmaceutical company told the US Court of Appeals for the First Circuit on Monday.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10